NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $16.90 +0.26 (+1.56 %) (As of 07/22/2018 04:00 PM ET)Previous Close$16.90Today's Range$16.57 - $16.9552-Week Range$14.40 - $20.45Volume144,702 shsAverage Volume203,085 shsMarket Capitalization$787.78 millionP/E Ratio44.47Dividend YieldN/ABeta1.34 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California. Receive AMPH News and Ratings via Email Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AMPH CUSIPN/A Webwww.amphastar.com Phone909-980-9484 Debt Debt-to-Equity Ratio0.12 Current Ratio2.40 Quick Ratio1.53 Price-To-Earnings Trailing P/E Ratio44.47 Forward P/E Ratio56.33 P/E Growth2.52 Sales & Book Value Annual Sales$240.18 million Price / Sales3.28 Cash Flow$0.7313 per share Price / Cash23.11 Book Value$7.34 per share Price / Book2.30 Profitability EPS (Most Recent Fiscal Year)$0.38 Net Income$4.50 million Net Margins-1.50% Return on Equity3.39% Return on Assets2.52% Miscellaneous Employees1,644 Outstanding Shares46,610,000Market Cap$787.78 Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions What is Amphastar Pharmaceuticals' stock symbol? Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH." How will Amphastar Pharmaceuticals' stock buyback program work? Amphastar Pharmaceuticals announced that its board has authorized a share buyback program on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced its earnings results on Wednesday, May, 9th. The company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.13. The firm had revenue of $58.40 million for the quarter, compared to the consensus estimate of $60.75 million. Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.39%. The company's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.09 earnings per share. View Amphastar Pharmaceuticals' Earnings History. What price target have analysts set for AMPH? 6 brokers have issued 1-year price objectives for Amphastar Pharmaceuticals' stock. Their predictions range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $21.20 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View Analyst Ratings for Amphastar Pharmaceuticals. What is the consensus analysts' recommendation for Amphastar Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Amphastar Pharmaceuticals' key competitors? Some companies that are related to Amphastar Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS) and Endo International (ENDP). Who are Amphastar Pharmaceuticals' key executives? Amphastar Pharmaceuticals' management team includes the folowing people: Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 68)Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 71)Mr. Jason B. Shandell, Pres & Director (Age 44)Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)Mr. Rong Zhou, Exec. VP of Production Center (Age 59) Has Amphastar Pharmaceuticals been receiving favorable news coverage? News stories about AMPH stock have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.20 on Accern's scale. They also assigned media stories about the company an impact score of 46.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.28%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals. Which institutional investors are selling Amphastar Pharmaceuticals stock? AMPH stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amphastar Pharmaceuticals' stock price today? One share of AMPH stock can currently be purchased for approximately $16.90. How big of a company is Amphastar Pharmaceuticals? Amphastar Pharmaceuticals has a market capitalization of $787.78 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe. How can I contact Amphastar Pharmaceuticals? Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected] MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 214 (Vote Outperform)Underperform Votes: 168 (Vote Underperform)Total Votes: 382MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?